Ipsen Seeks Success Outside Big Pharma's Hunting Grounds
Keen On Drugs With Peak Sales Of $300m-800m
David Loew has assembled a strong business development team which secured seven licensing pacts in 2021 and the Ipsen CEO tells Scrip that this year should see more of the same.
